Hardwicke is delighted to announce that Mark Engelman will be speaking at CDR’s Life Sciences Litigation Symposium at the Sofitel St James, London, on 18 June.
The agenda is tailored to the unique needs of stakeholders in the life science sector, enabling them to discuss current issues, react to changing demands of regulators and lawmakers, and furnish appropriate strategic and operational responses to the needs of their patent portfolios.
Taking the right steps to maximise patent term and seek patent protection, the panel will empower your strategic goals and enhance legal relationships with core business units.
- Understand the benefit and impact of patent research to deliver wider business benefits
- Map your value-extending strategies for new formulation and rising cost of drug development
- Incorporate LOE strategic pathways including prevention, innovation, extraction and adaption to maximise patent protection and profit
- Understand how the unified system has streamlined patent approval process through the use of both legal and technical experts via Unitary Patent Court (UPC)
Further information can be found here.
